Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Safety

• Publication date

  2016-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40264-016-0408-yPMID 26951234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Why Most Published Research Findings Are False

  2019cited by this paper
• BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials

  2015cited by this paper
• Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration.

  2015cited by this paper
• Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

  2015cited by this paper
• Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.

  2015cited by this paper
• Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy.

  2015cited by this paper
• Systemic safety of anti-VEGF drugs: a commentary

  2015cited by this paper
• Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial.

  2015cited by this paper
• Prospective Comparison of Low-Fluence Photodynamic Therapy Combined with Intravitreal Bevacizumab versus Bevacizumab Monotherapy for Choroidal Neovascularization in Age-Related Macular Degeneration

  2015cited by this paper
• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview

  2014cited by this paper
• Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

  2014cited by this paper
• Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

  2014cited by this paper
• Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

  2014cited by this paper
• Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

  2014cited by this paper
• Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials

  2014cited by this paper
• Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

  2013cited by this paper
• A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

  2013cited by this paper
• INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Effect of Baseline Visual Acuity

  2013cited by this paper
• Bevacizumab in age‐related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

  2013cited by this paper
• Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation

  2013cited by this paper
• Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

  2013cited by this paper
• Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

  2013cited by this paper
• MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study

  2013cited by this paper
• The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews

  2013cited by this paper
• Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.

  2013cited by this paper
• Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)

  2013cited by this paper
• Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

  2012cited by this paper
• RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3-Year Follow-up Results

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration

  2012cited by this paper
• Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.

  2012cited by this paper
• Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡*

  2012cited by this paper
• Age-Related Macular Degeneration and Long-Term Risk of Stroke Subtypes

  2012cited by this paper
• Bevacizumab for neovascular age-related macular degeneration in China.

  2012cited by this paper
• Age-related macular degeneration

  2012cited by this paper
• Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study

  2012cited by this paper
• Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.

  2012cited by this paper
• Pharmacotherapy of Age-Related Macular Degeneration

  2012cited by this paper
• Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

  2011cited by this paper
• Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

  2011cited by this paper
• INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Six-Month Results of a Randomized Clinical Trial

  2011cited by this paper
• The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

  2011cited by this paper
• GRADE guidelines: 8. Rating the quality of evidence--indirectness.

  2011cited by this paper
• Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration.

  2011cited by this paper
• Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab

  2011cited by this paper
• Interpretation of random effects meta-analyses

  2011cited by this paper
• GRADE guidelines: 7. Rating the quality of evidence--inconsistency.

  2011cited by this paper
• Efficacy of 12‐month treatment of neovascular age‐related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections

  2011cited by this paper
• VITREOUS AND PLASMA CONCENTRATIONS OF APELIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL BEVACIZUMAB IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY

  2011cited by this paper
• Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.

  2010cited by this paper
• The effect of methotrexate on corneal neovascularization in rabbits.

  2010cited by this paper
• INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY: One-Year Results

  2010cited by this paper
• Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

  2010cited by this paper
• Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.

  2010cited by this paper
• Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

  2010cited by this paper
• Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

  2010cited by this paper
• Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study

  2009cited by this paper
• Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results

  2009cited by this paper
• A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study

  2009cited by this paper
• VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Randomized, Controlled Trial

  2009cited by this paper
• INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAÏVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A 12-Month Follow-Up Study

  2009cited by this paper
• Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

  2009cited by this paper
• Regulating off-label drug use--rethinking the role of the FDA.

  2008cited by this paper
• Special Topics in Statistics

  2008cited by this paper
• Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration

  2008cited by this paper
• SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE

  2008cited by this paper
• Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

  2008cited by this paper
• Chapter 16: Special Topics in Statistics

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age‐related macular degeneration of different durations

  2008cited by this paper
• Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

  2008cited by this paper
• Clinical update: new treatments for age-related macular degeneration.

  2007cited by this paper
• Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

  2007cited by this paper
• Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

  2007cited by this paper
• Uncertainty in heterogeneity estimates in meta-analyses

  2007cited by this paper
• Why Most Published Research Findings Are False

  2005cited by this paper
• Grading quality of evidence and strength of recommendations

  2004cited by this paper
• The power of statistical tests in meta-analysis.

  2001cited by this paper

• The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy

  2025cites this paper
• Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study

  2022cites this paper
• Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges.

  2021cites this paper
• Ganglion Cell Layer Thickness Change in Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Injections

  2021cites this paper
• Change in cardiac troponin T level after intravitreal anti-vascular endothelial growth factor treatment: Prospective pilot study

  2020cites this paper
• Circulating endothelial and progenitor cells in age-related macular degeneration

  2020cites this paper
• Complement factor B knockdown by short hairpin RNA inhibits laser-induced choroidal neovascularization in rats.

  2020cites this paper
• Surgical and Nonsurgical Trauma

  2020cites this paper
• Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration

  2019cites this paper
• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update

  2019cites this paper
• A Proximity Extension Assay (PEA)-based method for quantification of bevacizumab.

  2018cites this paper
• Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis

  2018cites this paper
• Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use

  2018cites this paper
• The association between myocardial infarction and intravitreal bevacizumab injection

  2018cites this paper
• Ranibizumab and digital ischemia.

  2018cites this paper
• Appraising the Quality of Systematic Reviews for Age-Related Macular Degeneration Interventions: A Systematic Review

  2018cites this paper
• FARMACI ANTI-VEGF INTRAVITREALI E RISCHIO CARDIOVASCOLARE: UN NUOVO CAMPO DI INTERESSE PER IL DIABETOLOGO?

  2018cites this paper
• FARMACI ANTI-VEGF INTRAVITREALI E RISCHIO CARDIOVASCOLARE: UN NUOVO CAMPO DI INTERESSE PER IL DIABETOLOGO?

  2018cites this paper
• Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States.

  2017cites this paper
• Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System

  2017cites this paper
• Discoveries of Targets and Novel Agents for the Treatment of Ischemic Retinopathy and Neovascular Disease

  2016cites this paper
• Drugs Used in Ocular Treatment

  2016cites this paper